





an Open Access Journal by MDPI

Personalized Medicine for Neuroimmunology and Epigenetics in Depressive Disorders

Guest Editors:

Prof. Dr. Piotr Galecki

Department of Adult Psychiatry, Medical University of Lodz, Lodz, Poland

Prof. Dr. Kuan-Pin Su

Department of Psychiatry and Mind-Body Interface Laboratory (MBI-Lab), China Medical University Hospital, Taichung, Taiwan

Deadline for manuscript submissions:

closed (5 January 2021)

Message from the Guest Editors

Depressive disorders are one of the most common mental disorders worldwide. They are a leading cause of disability. Despite their high prevalence, the etiopathogenesis of depressive disorders is not yet fully understood. The aim of recent studies in the field of psychiatry is to seek consistent theory that would exhaustively explain the aetiology of depression. Neuroimmunology, epigenetics, and their correlations seem to play an important role in this matter.

We would like to invite experts to participate in our Special Issue, in which we would like to focus on the biological background of depressive disorders. Nowadays, when one third of the patients suffer from treatment resistant depression, seeking for new therapeutic targets is especially important. Since depression also has a significant impact on socioeconomics, scientists are also seeking methods of its primary prevention.

Original research papers, brief scientific reports, as well as review papers, regarding the given topic, will be considered for publication in this Special Issue "Personalized Medicine for Neuroimmunology and Epigenetics in Depressive Disorders"













an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. David Alan Rizzieri

 Novant Health Cancer Institute, Winston-Salem, NC 27103, USA
Division of Hematologic Malignancies and Cellular Therapy, Duke University,

Durham, NC 27710, USA

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. JPM publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). JPM is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, and other databases.

Journal Rank: JCR - Q1 (Medicine, General and Internal) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us